P&T Community reports that the National Comprehensive Cancer Network (NCCN) Oncology Research Program has awarded grants to three clinical investigators from NCCN member institutions through a collaborative scientific research relationship with Taiho Oncology, Inc. to study the clinical effectiveness and safety of trifluridine and tipiracil (TAS-102) for treatment of various advanced, solid tumors. The investigators include:
Patrick Boland, MD Rosewell Park Comprehensive Cancer Center, a Phase II Study of TAS-102 Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO)
Amit Mahipal, MBBS, Mayo Clinic Cancer Center, Phase II Trial of trifluridine/tipiracil in Combination with Irinotecan in Biliary Tract Cancers
Sarbajit Mukherjee, MD, MS, Roswell Park Comprehensive Cancer Center, Use of Trifluridine/tipiracil and Oxaliplatin as Induction Chemotherapy in Respectable Esophageal and Gastroesophageal junction (GEJ) Adenocarcinoma
What is TAS-102?
Approved by the FDA in 2015 and EMA in 2016, trifluridine/tipiracil (trade name Lonsurf) is a combination drug that is approved for use as a third- or fourth-line treatment of metastatic colorectal c...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).